» Articles » PMID: 33154566

Imaging Synaptic Dopamine Availability in Individuals at Clinical High-risk for Psychosis: a [C]-(+)-PHNO PET with Methylphenidate Challenge Study

Overview
Journal Mol Psychiatry
Date 2020 Nov 6
PMID 33154566
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Patients at clinical high-risk (CHR) for psychosis show elevations in [F]DOPA uptake, an estimate of dopamine (DA) synthesis capacity, in the striatum predictive of conversion to schizophrenia. Intrasynaptic DA levels can be inferred from imaging the change in radiotracer binding at D receptors due to a pharmacological challenge. Here, we used methylphenidate, a DA reuptake inhibitor, and [C]-(+)-PHNO, to measure synaptic DA availability in CHR both in striatal and extra-striatal brain regions. Fourteen unmedicated, nonsubstance using CHR individuals and 14 matched control subjects participated in the study. Subjects underwent two [C]-(+)-PHNO scans, one at baseline and one following administration of a single oral dose (60 mg) of methylphenidate. [C]-(+)-PHNO BP, the binding potential relative to the nondisplaceable compartment, was derived using the simplified reference tissue model with cerebellum as reference tissue. The percent change in BP between scans, ΔBP, was computed as an index of synaptic DA availability, and group comparisons were performed with a linear mixed model. An overall trend was found for greater synaptic DA availability (∆BP) in CHR than controls (p = 0.06). This was driven entirely by ∆BP in ventral striatum (-34 ± 14% in CHR, -20 ± 12% in HC; p = 0.023). There were no significant group differences in any other brain region. There were no significant differences in DA transmission in any striatal region between converters and nonconverters, although this finding is limited by the small sample size (N = 2). There was a strong and negative correlation between ΔBP in VST and severity of negative symptoms at baseline in the CHR group (r = -0.66, p < 0.01). We show abnormally increased DA availability in the VST in CHR and an inverse relationship with negative symptoms. Our results suggest a potential early role for mesolimbic dopamine overactivity in CHR. Longitudinal studies are needed to ascertain the significance of the differential topography observed here with the [F]DOPA literature.

Citing Articles

Eating disorders and disordered eating symptoms in individuals at clinical high risk for psychosis: a systematic review and meta-analysis.

Lo Buglio G, Mirabella M, Muzi L, Boldrini T, Cerasti E, Bjornestad J Eat Weight Disord. 2024; 29(1):78.

PMID: 39729192 PMC: 11680612. DOI: 10.1007/s40519-024-01708-x.


The dopaminergic basis of negative symptoms in schizophrenia: an addendum.

Weidenauer A, Dajic I, Praschak-Rieder N, Willeit M Mol Psychiatry. 2024; 30(3):1167-1169.

PMID: 39567744 DOI: 10.1038/s41380-024-02828-7.


Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation.

Weidenauer A, Sauerzopf U, Bauer M, Bum C, Diendorfer C, Dajic I Schizophr Bull. 2024; 51(1):159-169.

PMID: 39137162 PMC: 11661945. DOI: 10.1093/schbul/sbae111.


Generalizability and Out-of-Sample Predictive Ability of Associations Between Neuromelanin-Sensitive Magnetic Resonance Imaging and Psychosis in Antipsychotic-Free Individuals.

Wengler K, Baker S, Velikovskaya A, Fogelson A, Girgis R, Reyes-Madrigal F JAMA Psychiatry. 2023; 81(2):198-208.

PMID: 37938847 PMC: 10633403. DOI: 10.1001/jamapsychiatry.2023.4305.


Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies.

Kositsyn Y, de Abreu M, Kolesnikova T, Lagunin A, Poroikov V, Harutyunyan H Int J Mol Sci. 2023; 24(11).

PMID: 37298431 PMC: 10253480. DOI: 10.3390/ijms24119482.


References
1.
Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F . The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2012; 70(1):107-20. PMC: 4356506. DOI: 10.1001/jamapsychiatry.2013.269. View

2.
Addington J, Cornblatt B, Cadenhead K, Cannon T, McGlashan T, Perkins D . At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011; 168(8):800-5. PMC: 3150607. DOI: 10.1176/appi.ajp.2011.10081191. View

3.
Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Valmaggia L . Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry. 2011; 168(12):1311-7. PMC: 3682447. DOI: 10.1176/appi.ajp.2011.11010160. View

4.
Egerton A, Chaddock C, Winton-Brown T, Bloomfield M, Bhattacharyya S, Allen P . Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013; 74(2):106-12. DOI: 10.1016/j.biopsych.2012.11.017. View

5.
Howes O, Montgomery A, Asselin M, Murray R, Valli I, Tabraham P . Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009; 66(1):13-20. DOI: 10.1001/archgenpsychiatry.2008.514. View